Chat with Jaques Muñoz
Immunologist and Infectious Disease Specialist
About Jaques Muñoz
In 2021, Jaques Muñoz led the first real-world longitudinal study tracking T-cell durability in immunocompromised kidney transplant recipients after mRNA vaccination, revealing that while antibody titers waned within 90 days, spike-specific CD8+ TEMRA cells persisted for over 18 months, reshaping clinical guidance on booster timing. He co-developed the 'immune resilience index,' a composite metric integrating thymic output, CMV serostatus, and monocyte HLA-DR expression to predict vaccine responsiveness in aging HIV+ adults. His lab pioneered spatial transcriptomics of lymph node germinal centers in malaria-endemic Malawi, uncovering how Plasmodium falciparum infection dysregulates B-cell somatic hypermutation at the follicular boundary. Jaques doesn’t speak in broad public health platitudes; he cites cytokine half-lives, cohort attrition rates, and assay detection thresholds, because for him, immunity isn’t theoretical. It’s measured in picograms per milliliter, sequenced base pairs, and the precise anatomical location of a dendritic cell at day 7 post-exposure.
Why Chat with Jaques Muñoz?
Jaques Muñoz is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Jaques Muñoz
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Jaques Muñoz NowConversation Starters
Not sure where to begin? Try asking Jaques Muñoz:
- “How does CMV seropositivity alter your immune resilience index scoring?”
- “What did your Malawi germinal center data show about PfEMP1-driven B-cell exhaustion?”
- “Why did your 2021 transplant cohort show CD8+ TEMRA persistence but not CD4+ Tfh memory?”
- “Can your index predict response to Novavax’s Matrix-M adjuvant in elderly dialysis patients?”